This result demonstrates a new therapeutic approach to limit plaque erosion in endothelial injury and further supports the role of PAD4 and NETs in superficial erosion, suggesting that the PAD4 inhibitor GSK484 may be a targeted agent for the treatment of atherosclerosis (Molinaro et al., 2021). This evidence concerns the gene PADI4 and atherosclerosis.